Long‐term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ‐cell tumours

Abstract

This combination had a toxicity profile that was acceptable and comparable with other third-line regimens. There were eight (36%) major responses. After a 6-year minimum follow-up, four (18%) patients were long-term disease-free survivors.